Evaluation of MB-CART2019.1 in Patients with Refractory Multiple Sclerosis: A Clinical Trial

The primary objective of the study is to evaluate the efficacy of **MB-CART2019.1** in patients with **refractory Multiple Sclerosis**. This is clinically relevant as refractory Multiple Sclerosis represents a challenging subset of the disease where patients do not respond to conventional therapies, necessitating the exploration of novel treatment options. The study aims to determine whether MB-CART2019.1 can provide a therapeutic benefit in this patient population.

The clinical trial involves participants diagnosed with **refractory Multiple Sclerosis**. The study population includes both male and female subjects, with an age range that encompasses adults and older adults. The trial population was selected to include a vulnerable population, although specific details regarding the total number of participants have not been provided by the sponsor. The study does not specify any particular lifestyle considerations such as diet, physical activity, or habits. Key inclusion or exclusion criteria have not been disclosed, and the main objective of the trial remains unspecified.

The clinical trial is designed to evaluate the efficacy and safety of MB-CART2019.1 in patients with **refractory Multiple Sclerosis**. This study is structured as a randomized, double-blind, controlled trial, ensuring that neither the participants nor the researchers know who is receiving the treatment or placebo, thereby minimizing bias. The trial is set to commence recruitment on August 30, 2025, and is anticipated to conclude by December 30, 2030, providing a comprehensive evaluation period.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit. During this visit, eligibility criteria will be assessed to ensure participants meet the necessary requirements for trial inclusion. Following successful screening, participants will be randomized into treatment groups. Throughout the trial, follow-up visits will be scheduled at regular intervals to monitor the participants' health, assess treatment efficacy, and record any adverse events. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to gather comprehensive data on the treatment's long-term effects.

The expected duration of participant involvement will vary depending on individual response to treatment and adherence to the study protocol. Participants may be subject to early termination from the study if they experience significant adverse effects, fail to comply with study procedures, or withdraw consent. The trial's design and procedures are meticulously crafted to ensure the collection of robust and reliable data, contributing to the understanding of MB-CART2019.1's potential benefits and risks in treating refractory Multiple Sclerosis.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it has been designated as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information in the source data, further details about the **experimental medication** and any **non-experimental treatments** cannot be provided. The trial documentation should be consulted for comprehensive information regarding the treatments used in this clinical trial.

The clinical trial is scheduled to commence recruitment on August 30, 2025, with an estimated completion date of December 30, 2030. The trial is categorized under phase 9, indicating an advanced stage of clinical research. Efficacy assessments will be conducted throughout the trial period, although specific parameters or endpoints for evaluating efficacy, such as symptom improvement scores or biomarker levels, are not detailed in the available data. The methods and schedule for measuring, collecting, and analyzing these efficacy parameters, as well as any tools or instruments involved, are not specified. The trial's primary and secondary endpoints remain unspecified, and no information is provided regarding the medical condition being studied or the main objective of the trial. The trial's design and execution will adhere to standard clinical trial protocols, ensuring rigorous and systematic evaluation of the investigational product's efficacy.